Litcius/Paper detail

Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial

Zheng Wang, Lixing Li, Peiran Huang, Hai‐Yan Tu, Xiangyu Zhang, Yu Lei, Fei Liang, Cheng Huang, Shuang–Jian Qiu, Qing‐Hai Ye, Zhen‐Bin Ding, Xiaowu Huang, Ying–Hong Shi, Kang Won Song, Hui‐Chuan Sun, Xiaoying Wang, Yongfeng Xu, Yu Yao, Qiang Gao, Lan Zhang, Jia Fan, Jian Zhou

2025˜The œLancet. Gastroenterology & hepatology6 citationsDOI

Topics & Concepts

MedicineCapecitabineIntrahepatic CholangiocarcinomaSurgical resectionInternal medicineOncologyAdjuvantSurgeryClinical trialBiliary tract cancerPhases of clinical researchAdjuvant therapyChemoradiotherapyResectionOverall survivalCurative treatmentRandomized controlled trialBiliary tractCancerGeneral surgeryChemotherapyGastroenterologyComplete responseSurgical proceduresNeoadjuvant therapyCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersLiver Diseases and Immunity
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial | Litcius